Chardan Capital Markets reiterated a Buy rating and $50.00 price target on uniQure BV (NASDAQ: QURE) following the FDA commissioner's ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments

uniQure (QURE), Others Gains Following Gottlieb Comments on Gene TherapyMay 22, 2018 12:48 PM Pre-Open Stock Movers 05/21: (MBFI) (NBRV) (SHLD) Higher; (PRTA) (QD) (APPF) Lower (more...)May 21, 2018 9:17 AM uniQure (QURE) Highlights New Data from Phase I/II Clinical trial of AMT-060 Showing Successful Liver Transduction with AAV5 Vector May 21, 2018 7:06 AM uniQure Presents New Data Demonstrating Clinical Benefit in Hemophilia B Patients with Pre-Existing Anti-AAV5 Neutralizing AntibodiesMay 21, 2018 7:00 AM